Scholarlink

<p>This study compared the efficacy and safety of tegoprazan versus proton-pump inhibitors (PPIs) for gastrointestinal (GI) protection in patients receiving dual antiplatelet therapy (DAPT) after undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Using a Korean Nationwide database (March 2019 to September 2022), 21,276 patients treated with tegoprazan (<i>n</i> = 2,075) or PPIs (<i>n</i> = 19,201) in combination with DAPT after PCI for AMI were analyzed. The primary efficacy endpoint was GI bleeding at 1 year, and the primary safety endpoint was major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of myocardial infarction or stroke. In the crude cohort, tegoprazan was associated with a lower risk of GI bleeding and major bleeding with similar MACCEs rates at 1 year compared to PPIs. After propensity-score matching, tegoprazan was consistently associated with lower risks of GI bleeding (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.54–0.98, <i>P</i> = 0.04) and major bleeding (HR 0.69, 95% CI 0.49–0.98, <i>P =</i> 0.04<i>)</i>, without increasing the risk of MACCEs (HR 0.86, 95% CI 0.59–1.26, <i>P</i> = 0.45) at 1 year. In patients with AMI treated with DAPT, tegoprazan was associated with a significantly lower GI bleeding risk versus PPIs, without increasing ischemic events.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of tegoprazan in patients treated with dual antiplatelet therapy after coronary stenting for acute myocardial infarction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Oh-Hyun Lee,
  • Seok-Jae Heo,
  • Seong Huan Choi,
  • Ji Woong Roh,
  • Eui Im,
  • Deok-Kyu Cho,
  • Yongcheol Kim

摘要

This study compared the efficacy and safety of tegoprazan versus proton-pump inhibitors (PPIs) for gastrointestinal (GI) protection in patients receiving dual antiplatelet therapy (DAPT) after undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Using a Korean Nationwide database (March 2019 to September 2022), 21,276 patients treated with tegoprazan (n = 2,075) or PPIs (n = 19,201) in combination with DAPT after PCI for AMI were analyzed. The primary efficacy endpoint was GI bleeding at 1 year, and the primary safety endpoint was major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of myocardial infarction or stroke. In the crude cohort, tegoprazan was associated with a lower risk of GI bleeding and major bleeding with similar MACCEs rates at 1 year compared to PPIs. After propensity-score matching, tegoprazan was consistently associated with lower risks of GI bleeding (hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.54–0.98, P = 0.04) and major bleeding (HR 0.69, 95% CI 0.49–0.98, P = 0.04), without increasing the risk of MACCEs (HR 0.86, 95% CI 0.59–1.26, P = 0.45) at 1 year. In patients with AMI treated with DAPT, tegoprazan was associated with a significantly lower GI bleeding risk versus PPIs, without increasing ischemic events.